{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T22:29:05Z","timestamp":1794004145435,"version":"4.8.0"},"reference-count":91,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-67865-4","type":"journal-article","created":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T10:02:39Z","timestamp":1769076159000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["CDK2 inhibitor BLU-222 synergizes with CDK4\/6 inhibitors in drug resistant breast cancers through p21\/p27 induction"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2365-0327","authenticated-orcid":false,"given":"Linjie","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9566-8975","authenticated-orcid":false,"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuyen","family":"Bui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoting","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8027-8990","authenticated-orcid":false,"given":"Mei-Kuang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiayu","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sepideh","family":"Mohammadhosseinpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6038-4144","authenticated-orcid":false,"given":"Mi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel Y.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saba","family":"Kamaliasl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen W.","family":"Ulizio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spyros","family":"Tsavachidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana","family":"Navarro-Yepes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2043-4407","authenticated-orcid":false,"given":"Nicole M.","family":"Kettner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Wingate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6816-6072","authenticated-orcid":false,"given":"Funda","family":"Meric-Bernstam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9156-8723","authenticated-orcid":false,"given":"Kelly K.","family":"Hunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5398-0802","authenticated-orcid":false,"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6504-160X","authenticated-orcid":false,"given":"Kerrie","family":"Faia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5440-0849","authenticated-orcid":false,"given":"Khandan","family":"Keyomarsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,22]]},"reference":[{"key":"67865_CR1","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nrc2602","volume":"9","author":"M Malumbres","year":"2009","unstructured":"Malumbres, M. & Barbacid, M. Cell cycle, CDKs and cancer: a changing paradigm. Nat. Rev. Cancer 9, 153\u2013166 (2009).","journal-title":"Nat. Rev. Cancer"},{"key":"67865_CR2","doi-asserted-by":"publisher","first-page":"774845","DOI":"10.3389\/fcell.2021.774845","volume":"9","author":"R Fagundes","year":"2021","unstructured":"Fagundes, R. & Teixeira, L. K. Cyclin E\/CDK2: DNA replication, replication stress and genomic instability. Front Cell Dev. Biol. 9, 774845 (2021).","journal-title":"Front Cell Dev. Biol."},{"key":"67865_CR3","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.drudis.2019.12.001","volume":"25","author":"S Tadesse","year":"2020","unstructured":"Tadesse, S. et al. Targeting CDK2 in cancer: challenges and opportunities for therapy. Drug Discov. Today 25, 406\u2013413 (2020).","journal-title":"Drug Discov. Today"},{"key":"67865_CR4","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1023\/A:1006353008903","volume":"17","author":"AM Senderowicz","year":"1999","unstructured":"Senderowicz, A. M. Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials. Invest N. Drugs 17, 313\u2013320 (1999).","journal-title":"Invest N. Drugs"},{"key":"67865_CR5","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1021\/ar0201198","volume":"36","author":"L Meijer","year":"2003","unstructured":"Meijer, L. & Raymond, E. Roscovitine and other purines as kinase inhibitors. From starfish oocytes to clinical trials. Acc. Chem. Res 36, 417\u2013425 (2003).","journal-title":"Acc. Chem. Res"},{"key":"67865_CR6","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1158\/1535-7163.MCT-10-0324","volume":"9","author":"D Parry","year":"2010","unstructured":"Parry, D. et al. Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor. Mol. Cancer Ther. 9, 2344\u20132353 (2010).","journal-title":"Mol. Cancer Ther."},{"key":"67865_CR7","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.clbc.2013.10.016","volume":"14","author":"MM Mita","year":"2014","unstructured":"Mita, M. M. et al. Randomized phase II trial of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus capecitabine in patients with advanced breast cancer. Clin. Breast Cancer 14, 169\u2013176 (2014).","journal-title":"Clin. Breast Cancer"},{"key":"67865_CR8","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1158\/2159-8290.CD-23-0954","volume":"14","author":"C Dietrich","year":"2024","unstructured":"Dietrich, C. et al. INX-315, a selective CDK2 inhibitor, induces cell cycle arrest and senescence in solid tumors. Cancer Discov. 14, 446\u2013467 (2024).","journal-title":"Cancer Discov."},{"key":"67865_CR9","doi-asserted-by":"crossref","unstructured":"House N. C. et al. Profiling the Activity of the Potent and Highly Selective CDK2 Inhibitor BLU-222 Reveals Determinants of Response in CCNE1-Aberrant Ovarian and Endometrial Tumors. Cancer 85, 1297\u20131309 (2025).","DOI":"10.1158\/0008-5472.CAN-24-2360"},{"key":"67865_CR10","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1073\/pnas.0900121106","volume":"107","author":"P Hydbring","year":"2010","unstructured":"Hydbring, P. et al. Phosphorylation by Cdk2 is required for Myc to repress Ras-induced senescence in cotransformation. Proc. Natl. Acad. Sci. USA 107, 58\u201363 (2010).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"67865_CR11","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.ccr.2005.05.006","volume":"7","author":"A Mart\u00edn","year":"2005","unstructured":"Mart\u00edn, A. et al. Cdk2 is dispensable for cell cycle inhibition and tumor suppression mediated by p27Kip1 and p21Cip1. Cancer Cell 7, 591\u2013598 (2005).","journal-title":"Cancer Cell"},{"key":"67865_CR12","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1158\/1541-7786.MCR-14-0163","volume":"13","author":"H Zalzali","year":"2015","unstructured":"Zalzali, H. et al. CDK2 transcriptional repression is an essential effector in p53-dependent cellular senescence\u2014implications for therapeutic intervention. Mol. Cancer Res. 13, 29\u201340 (2015).","journal-title":"Mol. Cancer Res."},{"key":"67865_CR13","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s12943-024-01973-5","volume":"23","author":"A Zingoni","year":"2024","unstructured":"Zingoni, A. et al. The senescence journey in cancer immunoediting. Mol. Cancer 23, 68 (2024).","journal-title":"Mol. Cancer"},{"key":"67865_CR14","doi-asserted-by":"publisher","first-page":"5481","DOI":"10.1158\/0008-5472.CAN-18-1235","volume":"78","author":"JA Caruso","year":"2018","unstructured":"Caruso, J. A., Duong, M. T., Carey, J. P. W., Hunt, K. K. & Keyomarsi, K. Low-molecular-weight cyclin E in human cancer: cellular consequences and opportunities for targeted therapies. Cancer Res. 78, 5481\u20135491 (2018).","journal-title":"Cancer Res."},{"key":"67865_CR15","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1016\/j.ajpath.2016.02.024","volume":"186","author":"C Karakas","year":"2016","unstructured":"Karakas, C. et al. Cytoplasmic cyclin E and phospho-cyclin-dependent kinase 2 are biomarkers of aggressive breast cancer. Am. J. Pathol. 186, 1900\u20131912 (2016).","journal-title":"Am. J. Pathol."},{"key":"67865_CR16","first-page":"2217","volume":"10","author":"KK Hunt","year":"2016","unstructured":"Hunt, K. K. et al. Cytoplasmic cyclin E predicts recurrence in patients with breast cancer. Clin. Cancer Res. 10, 2217 (2016).","journal-title":"Clin. Cancer Res."},{"key":"67865_CR17","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s11523-017-0541-2","volume":"13","author":"S Vijayaraghavan","year":"2017","unstructured":"Vijayaraghavan, S., Moulder, S., Keyomarsi, K. & Layman, R. M. Inhibiting CDK in cancer therapy: current evidence and future directions. Target Oncol. 13, 21\u201338 (2017).","journal-title":"Target Oncol."},{"key":"67865_CR18","doi-asserted-by":"publisher","first-page":"15916","DOI":"10.1038\/ncomms15916","volume":"8","author":"S Vijayaraghavan","year":"2017","unstructured":"Vijayaraghavan, S. et al. CDK4\/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers. Nat. Commun. 8, 15916 (2017).","journal-title":"Nat. Commun."},{"key":"67865_CR19","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1016\/j.cell.2023.05.013","volume":"186","author":"M Arora","year":"2023","unstructured":"Arora, M. et al. Rapid adaptation to CDK2 inhibition exposes intrinsic cell-cycle plasticity. Cell 186, 2628\u20132643 e2621 (2023).","journal-title":"Cell"},{"key":"67865_CR20","doi-asserted-by":"publisher","unstructured":"Kawakami, M. et al. Next-generation CDK2\/9 inhibitors and anaphase catastrophe in lung cancer. J. Natl. Cancer Inst. 109 https:\/\/doi.org\/10.1093\/jnci\/djw297 (2017).","DOI":"10.1093\/jnci\/djw297"},{"key":"67865_CR21","doi-asserted-by":"publisher","unstructured":"Schomer, N. et al. CDK2 inhibition demonstrates synthetic lethality in SCLC through apoptotic induction. Mol. Cancer Therapeutics 22 https:\/\/doi.org\/10.1158\/1535-7163.Targ-23-A022 (2023).","DOI":"10.1158\/1535-7163.Targ-23-A022"},{"key":"67865_CR22","doi-asserted-by":"publisher","unstructured":"Patel, M. R. et al. BLU-222, an oral, potent, and selective CDK2 inhibitor, in patients with advanced solid tumors: phase 1 monotherapy dose escalation. J. Clin. Oncol. 41 https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.3095 (2023).","DOI":"10.1200\/JCO.2023.41.16_suppl.3095"},{"key":"67865_CR23","doi-asserted-by":"crossref","unstructured":"Yap, T. A. et al. in Annals of Oncology 33, S765-S765 (2022).","DOI":"10.1016\/j.annonc.2022.07.619"},{"key":"67865_CR24","doi-asserted-by":"crossref","unstructured":"Juric, D. et al. BLU-222, an investigational, oral, potent, and highly selective CDK2 inhibitor (CDK2i), as monotherapy in patients (pts) with advanced solid tumors and in combination with ribociclib (RIBO) and fulvestrant (FUL) in HR+\/HER2-breast cancer (BC). J. Clin. Oncol. 42, 1056 (2024).","DOI":"10.1200\/JCO.2024.42.16_suppl.1056"},{"key":"67865_CR25","doi-asserted-by":"publisher","first-page":"3864","DOI":"10.1158\/0008-5472.CAN-23-4130","volume":"84","author":"M Li","year":"2024","unstructured":"Li, M. et al. Low molecular weight cyclin E confers a vulnerability to PKMYT1 inhibition in triple-negative breast cancer. Cancer Res. 84, 3864\u20133880 (2024).","journal-title":"Cancer Res."},{"key":"67865_CR26","doi-asserted-by":"publisher","first-page":"5074","DOI":"10.1158\/0008-5472.CAN-09-4094","volume":"70","author":"R Bagheri-Yarmand","year":"2010","unstructured":"Bagheri-Yarmand, R., Biernacka, A., Hunt, K. K. & Keyomarsi, K. Low molecular weight cyclin E overexpression shortens mitosis, leading to chromosome missegregation and centrosome amplification. Cancer Res. 70, 5074\u20135084 (2010).","journal-title":"Cancer Res."},{"key":"67865_CR27","doi-asserted-by":"publisher","first-page":"3165","DOI":"10.1158\/0008-5472.CAN-23-2608","volume":"83","author":"HF Wingate","year":"2023","unstructured":"Wingate, H. F. & Keyomarsi, K. Distinct mechanisms of resistance to CDK4\/6 inhibitors require specific subsequent treatment strategies: one size does not fit all. Cancer Res. 83, 3165\u20133167 (2023).","journal-title":"Cancer Res."},{"key":"67865_CR28","doi-asserted-by":"publisher","first-page":"3264","DOI":"10.1158\/0008-5472.CAN-23-0705","volume":"83","author":"J Navarro-Yepes","year":"2023","unstructured":"Navarro-Yepes, J. et al. Abemaciclib is effective in palbociclib-resistant hormone receptor-positive metastatic breast cancers. Cancer Res 83, 3264\u20133283 (2023).","journal-title":"Cancer Res"},{"key":"67865_CR29","doi-asserted-by":"publisher","first-page":"3996","DOI":"10.1158\/1078-0432.CCR-18-3274","volume":"25","author":"NM Kettner","year":"2019","unstructured":"Kettner, N. M. et al. Combined inhibition of STAT3 and DNA repair in palbociclib-resistant ER-positive breast cancer. Clin. Cancer Res. 25, 3996\u20134013 (2019).","journal-title":"Clin. Cancer Res."},{"key":"67865_CR30","doi-asserted-by":"publisher","first-page":"R15","DOI":"10.1530\/ERC-18-0317","volume":"26","author":"N Portman","year":"2019","unstructured":"Portman, N. et al. Overcoming CDK4\/6 inhibitor resistance in ER-positive breast cancer. Endocr. Relat. Cancer 26, R15\u2013R30 (2019).","journal-title":"Endocr. Relat. Cancer"},{"key":"67865_CR31","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1158\/0008-5472.CAN-15-0728","volume":"76","author":"MT Herrera-Abreu","year":"2016","unstructured":"Herrera-Abreu, M. T. et al. Early adaptation and acquired resistance to CDK4\/6 inhibition in estrogen receptor-positive breast cancer. Cancer Res 76, 2301\u20132313 (2016).","journal-title":"Cancer Res"},{"key":"67865_CR32","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1200\/JCO.18.00925","volume":"37","author":"NC Turner","year":"2019","unstructured":"Turner, N. C. et al. Cyclin E1 expression and palbociclib efficacy in previously treated hormone receptor-positive metastatic breast cancer. J. Clin. Oncol. 37, 1169\u20131178 (2019).","journal-title":"J. Clin. Oncol."},{"key":"67865_CR33","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41523-018-0092-4","volume":"4","author":"C Guarducci","year":"2018","unstructured":"Guarducci, C. et al. Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancer. npj Breast Cancer 4, 38 (2018).","journal-title":"npj Breast Cancer"},{"key":"67865_CR34","doi-asserted-by":"publisher","first-page":"100110","DOI":"10.1016\/j.crphar.2022.100110","volume":"3","author":"D Duarte","year":"2022","unstructured":"Duarte, D. & Vale, N. Evaluation of synergism in drug combinations and reference models for future orientations in oncology. Curr. Res Pharm. Drug Discov. 3, 100110 (2022).","journal-title":"Curr. Res Pharm. Drug Discov."},{"key":"67865_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/bcr2419","volume":"11","author":"RS Finn","year":"2009","unstructured":"Finn, R. S. et al. PD 0332991, a selective cyclin D kinase 4\/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res. 11, 1\u201313 (2009).","journal-title":"Breast Cancer Res."},{"key":"67865_CR36","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/0092-8674(93)90499-G","volume":"75","author":"JW Harper","year":"1993","unstructured":"Harper, J. W., Adami, G. R., Wei, N., Keyomarsi, K. & Elledge, S. J. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75, 805\u2013816 (1993).","journal-title":"Cell"},{"key":"67865_CR37","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/0092-8674(93)90500-P","volume":"75","author":"WS el-Deiry","year":"1993","unstructured":"el-Deiry, W. S. et al. WAF1, a potential mediator of p53 tumor suppression. Cell 75, 817\u2013825 (1993).","journal-title":"Cell"},{"key":"67865_CR38","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/nrc2657","volume":"9","author":"T Abbas","year":"2009","unstructured":"Abbas, T. & Dutta, A. p21 in cancer: intricate networks and multiple activities. Nat. Rev. Cancer 9, 400\u2013414 (2009).","journal-title":"Nat. Rev. Cancer"},{"key":"67865_CR39","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1101\/gad.8.1.9","volume":"8","author":"K Polyak","year":"1994","unstructured":"Polyak, K. et al. p27KIP1, a cyclin-cdk inhibitor, links transforming growth factor\u00df and contact inhibition to cell cycle arrest. Genes Dev. 8, 9\u201322 (1994).","journal-title":"Genes Dev."},{"key":"67865_CR40","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1002\/(SICI)1097-4652(200004)183:1<10::AID-JCP2>3.0.CO;2-I","volume":"183","author":"J Slingerland","year":"2000","unstructured":"Slingerland, J. & Pagano, M. Regulation of the cdk inhibitor p27 and its deregulation in cancer. J. Cell Physiol. 183, 10\u201317 (2000).","journal-title":"J. Cell Physiol."},{"key":"67865_CR41","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1038\/s41698-025-01041-1","volume":"9","author":"NM Kettner","year":"2025","unstructured":"Kettner, N. M. et al. IL-6 predicts CDK4\/6 inhibitor resistance, identifying STAT3 as a target in HR + \/HER2-negative metastatic breast cancer. NPJ Precis Oncol. 9, 260 (2025).","journal-title":"NPJ Precis Oncol."},{"key":"67865_CR42","doi-asserted-by":"publisher","first-page":"6594","DOI":"10.1158\/1078-0432.CCR-18-1446","volume":"24","author":"X Chen","year":"2018","unstructured":"Chen, X. et al. Cyclin E overexpression sensitizes triple-negative breast cancer to wee1 kinase inhibition. Clin. Cancer Res. 24, 6594\u20136610 (2018).","journal-title":"Clin. Cancer Res."},{"key":"67865_CR43","doi-asserted-by":"publisher","first-page":"6468","DOI":"10.1158\/1078-0432.CCR-17-0615","volume":"23","author":"KW Evans","year":"2017","unstructured":"Evans, K. W. et al. A population of heterogeneous breast cancer patient-derived xenografts demonstrate broad activity of PARP inhibitor in BRCA1\/2 wild-type tumors. Clin. Cancer Res. 23, 6468\u20136477 (2017).","journal-title":"Clin. Cancer Res."},{"key":"67865_CR44","doi-asserted-by":"publisher","first-page":"3377","DOI":"10.1158\/0008-5472.CAN-10-4086","volume":"71","author":"S Akli","year":"2011","unstructured":"Akli, S., Van Pelt, C. S., Bui, T., Meijer, L. & Keyomarsi, K. Cdk2 is required for breast cancer mediated by the low-molecular-weight isoform of cyclin E. Cancer Res. 71, 3377\u20133386 (2011).","journal-title":"Cancer Res."},{"key":"67865_CR45","doi-asserted-by":"publisher","first-page":"7212","DOI":"10.1158\/0008-5472.CAN-07-0599","volume":"67","author":"S Akli","year":"2007","unstructured":"Akli, S. et al. Overexpression of the low molecular weight cyclin E in transgenic mice induces metastatic mammary carcinomas through the disruption of the ARF-p53 pathway. Cancer Res. 67, 7212\u20137222 (2007).","journal-title":"Cancer Res."},{"key":"67865_CR46","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/sj.onc.1201529","volume":"16","author":"M Mandal","year":"1998","unstructured":"Mandal, M., Bandyopadhyay, D., Goepfert, T. M. & Kumar, R. Interferon-induces expression of cyclin-dependent kinase-inhibitors p21WAF1 and p27Kip1 that prevent activation of cyclin-dependent kinase by CDK-activating kinase (CAK). Oncogene 16, 217\u2013225 (1998).","journal-title":"Oncogene"},{"key":"67865_CR47","doi-asserted-by":"publisher","first-page":"16448","DOI":"10.1073\/pnas.0607830103","volume":"103","author":"S Xiao","year":"2006","unstructured":"Xiao, S. et al. RIG-G as a key mediator of the antiproliferative activity of interferon-related pathways through enhancing p21 and p27 proteins. Proc. Natl. Acad. Sci. USA 103, 16448\u201316453 (2006).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"67865_CR48","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/s41581-022-00601-z","volume":"18","author":"W Huang","year":"2022","unstructured":"Huang, W., Hickson, L. J., Eirin, A., Kirkland, J. L. & Lerman, L. O. Cellular senescence: the good, the bad and the unknown. Nat. Rev. Nephrol. 18, 611\u2013627 (2022).","journal-title":"Nat. Rev. Nephrol."},{"key":"67865_CR49","doi-asserted-by":"publisher","first-page":"37","DOI":"10.18632\/aging.100527","volume":"5","author":"EA Georgakopoulou","year":"2013","unstructured":"Georgakopoulou, E. A. et al. Specific lipofuscin staining as a novel biomarker to detect replicative and stress-induced senescence. A method applicable in cryo-preserved and archival tissues. Aging 5, 37\u201350 (2013).","journal-title":"Aging"},{"key":"67865_CR50","doi-asserted-by":"publisher","first-page":"6070","DOI":"10.1093\/nar\/gkw523","volume":"44","author":"M Fischer","year":"2016","unstructured":"Fischer, M., Grossmann, P., Padi, M. & DeCaprio, J. A. Integration of TP53, DREAM, MMB-FOXM1 and RB-E2F target gene analyses identifies cell cycle gene regulatory networks. Nucleic Acids Res. 44, 6070\u20136086 (2016).","journal-title":"Nucleic Acids Res."},{"key":"67865_CR51","doi-asserted-by":"publisher","first-page":"6860","DOI":"10.1093\/nar\/gkv593","volume":"43","author":"S Orlando","year":"2015","unstructured":"Orlando, S. et al. p27Kip1 and p21Cip1 collaborate in the regulation of transcription by recruiting cyclin-Cdk complexes on the promoters of target genes. Nucleic Acids Res. 43, 6860\u20136873 (2015).","journal-title":"Nucleic Acids Res."},{"key":"67865_CR52","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.ccell.2020.03.010","volume":"37","author":"M Alvarez-Fernandez","year":"2020","unstructured":"Alvarez-Fernandez, M. & Malumbres, M. Mechanisms of sensitivity and resistance to CDK4\/6 inhibition. Cancer Cell 37, 514\u2013529 (2020).","journal-title":"Cancer Cell"},{"key":"67865_CR53","doi-asserted-by":"publisher","unstructured":"Guiley, K. Z. et al. p27 allosterically activates cyclin-dependent kinase 4 and antagonizes palbociclib inhibition. Science 366 https:\/\/doi.org\/10.1126\/science.aaw2106 (2019).","DOI":"10.1126\/science.aaw2106"},{"key":"67865_CR54","doi-asserted-by":"publisher","first-page":"5905","DOI":"10.1038\/s41388-019-0850-2","volume":"38","author":"C Zhang","year":"2019","unstructured":"Zhang, C. et al. Signalling involving MET and FAK supports cell division independent of the activity of the cell cycle-regulating CDK4\/6 kinases. Oncogene 38, 5905\u20135920 (2019).","journal-title":"Oncogene"},{"key":"67865_CR55","doi-asserted-by":"publisher","first-page":"4907","DOI":"10.18632\/oncotarget.27127","volume":"10","author":"M Iida","year":"2019","unstructured":"Iida, M. et al. The p21 levels have the potential to be a monitoring marker for ribociclib in breast cancer. Oncotarget 10, 4907\u20134918 (2019).","journal-title":"Oncotarget"},{"key":"67865_CR56","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s12943-024-02029-4","volume":"23","author":"S Poulet","year":"2024","unstructured":"Poulet, S. et al. Genome-wide in vivo CRISPR screen identifies TGF\u03b23 as actionable biomarker of palbociclib resistance in triple negative breast cancer. Mol. Cancer 23, 118 (2024).","journal-title":"Mol. Cancer"},{"key":"67865_CR57","doi-asserted-by":"publisher","first-page":"3356","DOI":"10.1038\/s41467-021-23612-z","volume":"12","author":"LR Pack","year":"2021","unstructured":"Pack, L. R., Daigh, L. H., Chung, M. & Meyer, T. Clinical CDK4\/6 inhibitors induce selective and immediate dissociation of p21 from cyclin D-CDK4 to inhibit CDK2. Nat. Commun. 12, 3356 (2021).","journal-title":"Nat. Commun."},{"key":"67865_CR58","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1006\/excr.1996.0264","volume":"227","author":"AL Gartel","year":"1996","unstructured":"Gartel, A. L. et al. p21 expression is induced in newly nondividing cells in diverse epithelial and during differentiation of the Caco-2 intestinal cell line. Exp. Cell Res. 227, 171\u2013181 (1996).","journal-title":"Exp. Cell Res."},{"key":"67865_CR59","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.gde.2014.06.009","volume":"26","author":"F Rossiello","year":"2014","unstructured":"Rossiello, F., Herbig, U., Longhese, M. P., Fumagalli, M. & d\u2019Adda di Fagagna, F. Irreparable telomeric DNA damage and persistent DDR signalling as a shared causative mechanism of cellular senescence and ageing. Curr. Opin. Genet Dev. 26, 89\u201395 (2014).","journal-title":"Curr. Opin. Genet Dev."},{"key":"67865_CR60","doi-asserted-by":"publisher","first-page":"645593","DOI":"10.3389\/fcell.2021.645593","volume":"9","author":"R Kumari","year":"2021","unstructured":"Kumari, R. & Jat, P. Mechanisms of cellular senescence: cell cycle arrest and senescence associated secretory phenotype. Front Cell Dev. Biol. 9, 645593 (2021).","journal-title":"Front Cell Dev. Biol."},{"key":"67865_CR61","doi-asserted-by":"publisher","first-page":"4661","DOI":"10.4161\/cc.22917","volume":"11","author":"M Quaas","year":"2012","unstructured":"Quaas, M., Muller, G. A. & Engeland, K. p53 can repress transcription of cell cycle genes through a p21(WAF1\/CIP1)-dependent switch from MMB to DREAM protein complex binding at CHR promoter elements. Cell Cycle 11, 4661\u20134672 (2012).","journal-title":"Cell Cycle"},{"key":"67865_CR62","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1158\/0008-5472.CAN-24-2244","volume":"85","author":"AP Dommer","year":"2025","unstructured":"Dommer, A. P. et al. Tumor Suppressors Condition Differential Responses to the Selective CDK2 Inhibitor BLU-222. Cancer Res. 85, 1310\u20131326 (2025).","journal-title":"Cancer Res."},{"key":"67865_CR63","doi-asserted-by":"publisher","first-page":"5105","DOI":"10.1038\/s41467-020-18872-0","volume":"11","author":"J Lyu","year":"2020","unstructured":"Lyu, J. et al. Synthetic lethality of RB1 and aurora A is driven by stathmin-mediated disruption of microtubule dynamics. Nat. Commun. 11, 5105 (2020).","journal-title":"Nat. Commun."},{"key":"67865_CR64","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.cell.2013.08.062","volume":"155","author":"SL Spencer","year":"2013","unstructured":"Spencer, S. L. et al. The proliferation-quiescence decision is controlled by a bifurcation in CDK2 activity at mitotic exit. Cell 155, 369\u2013383 (2013).","journal-title":"Cell"},{"key":"67865_CR65","doi-asserted-by":"publisher","first-page":"3864","DOI":"10.1158\/0008-5472.CAN-23-4130","volume":"84","author":"M Li","year":"2024","unstructured":"Li, M. et al. Low\u2013molecular weight cyclin E confers a vulnerability to PKMYT1 inhibition in triple-negative breast cancer. Cancer Res. 84, 3864\u20133880 (2024).","journal-title":"Cancer Res."},{"key":"67865_CR66","doi-asserted-by":"publisher","unstructured":"Luo, L. J. et al. Combination treatment with CDK2 inhibitor (BLU-222) and either palbociclib or ribociclib is synergistic in pre-clinical models of CDK4\/6 inhibitor-resistant breast cancer. Cancer Res. 84 https:\/\/doi.org\/10.1158\/1538-7445.Sabcs23-Po1-18-05 (2024).","DOI":"10.1158\/1538-7445.Sabcs23-Po1-18-05"},{"key":"67865_CR67","doi-asserted-by":"publisher","unstructured":"Luo, L. J. et al. Anti-tumor activity of CDK2 inhibitor BLU-222 in combination with CDK4\/6 inhibitors for overcoming resistance in HR positive and triple negative metastatic breast cancers models. Cancer Res. 84 https:\/\/doi.org\/10.1158\/1538-7445.Am2024-4622 (2023).","DOI":"10.1158\/1538-7445.Am2024-4622"},{"key":"67865_CR68","doi-asserted-by":"publisher","unstructured":"Brown, V. et al. CDK2 inhibition with BLU-222 in combination with ribociclib demonstrates robust antitumor activity in pre-clinical models of CDK4\/6 inhibitor-naive and -resistant HR+\/HER2-breast cancer. Cancer Res. 83 https:\/\/doi.org\/10.1158\/1538-7445.Sabcs22-P6-10-07 (2023).","DOI":"10.1158\/1538-7445.Sabcs22-P6-10-07"},{"key":"67865_CR69","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1038\/s42003-023-05412-x","volume":"6","author":"H Fan","year":"2023","unstructured":"Fan, H. et al. DNA damage induced by CDK4 and CDK6 blockade triggers anti-tumor immune responses through cGAS-STING pathway. Commun. Biol. 6, 1041 (2023).","journal-title":"Commun. Biol."},{"key":"67865_CR70","doi-asserted-by":"publisher","first-page":"e150","DOI":"10.1097\/SLA.0000000000003551","volume":"274","author":"C Karakas","year":"2021","unstructured":"Karakas, C. et al. Cytoplasmic cyclin E expression predicts for response to neoadjuvant chemotherapy in breast cancer. Ann. Surg. 274, e150\u2013e159 (2021).","journal-title":"Ann. Surg."},{"key":"67865_CR71","doi-asserted-by":"crossref","unstructured":"Yap, T. A. et al. First-in-human phase 1\/2a study of a potent and novel CDK2-selective inhibitor PF-07104091 in patients (pts) with advanced solid tumors, enriched for CDK4\/6 inhibitor resistant HR+\/HER2-breast cancer. J. Clin. Oncol. 41, 3010 (2023).","DOI":"10.1200\/JCO.2023.41.16_suppl.3010"},{"key":"67865_CR72","doi-asserted-by":"publisher","unstructured":"Shen, C. et al. PF-07104091, a first-in-class CDK2-selective inhibitor for the treatment of HR+\/HER2-breast cancer and CCNE1high ovarian cancer. Cancer Res. 84 https:\/\/doi.org\/10.1158\/1538-7445.Am2024-5709 (2023).","DOI":"10.1158\/1538-7445.Am2024-5709"},{"key":"67865_CR73","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1158\/0008-5472.CAN-22-2258","volume":"83","author":"TDT Nguyen","year":"2023","unstructured":"Nguyen, T. D. T. et al. Sequential targeting of retinoblastoma and DNA synthesis pathways is a therapeutic strategy for sarcomas that can be monitored in real time. Cancer Res 83, 939\u2013955 (2023).","journal-title":"Cancer Res"},{"key":"67865_CR74","doi-asserted-by":"publisher","first-page":"5331","DOI":"10.1038\/s41388-022-02527-z","volume":"41","author":"M Li","year":"2022","unstructured":"Li, M. et al. Low-molecular-weight cyclin E deregulates DNA replication and damage repair to promote genomic instability in breast cancer. Oncogene 41, 5331\u20135346 (2022).","journal-title":"Oncogene"},{"key":"67865_CR75","doi-asserted-by":"publisher","first-page":"3198","DOI":"10.1158\/0008-5472.CAN-03-3672","volume":"64","author":"S Akli","year":"2004","unstructured":"Akli, S. et al. Tumor-specific low molecular weight forms of cyclin E induce genomic instability and resistance to p21, p27, and antiestrogens in breast cancer. Cancer Res. 64, 3198\u20133208 (2004).","journal-title":"Cancer Res."},{"key":"67865_CR76","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.cmpb.2008.08.006","volume":"94","author":"A Allalou","year":"2009","unstructured":"Allalou, A. & Wahlby, C. BlobFinder, a tool for fluorescence microscopy image cytometry. Comput Methods Prog. Biomed. 94, 58\u201365 (2009).","journal-title":"Comput Methods Prog. Biomed."},{"key":"67865_CR77","doi-asserted-by":"crossref","unstructured":"Davan-Wetton, C. S., & Montero-Melendez, T. An optimised protocol for the detection of lipofuscin, a versatile and quantifiable marker of cellular senescence. Plos one 19, e0306275 (2024).","DOI":"10.1371\/journal.pone.0306275"},{"key":"67865_CR78","doi-asserted-by":"publisher","first-page":"R36","DOI":"10.1186\/gb-2013-14-4-r36","volume":"14","author":"D Kim","year":"2013","unstructured":"Kim, D. et al. TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol. 14, R36 (2013).","journal-title":"Genome Biol."},{"key":"67865_CR79","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1093\/bioinformatics\/btt656","volume":"30","author":"Y Liao","year":"2014","unstructured":"Liao, Y., Smyth, G. K. & Shi, W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics 30, 923\u2013930 (2014).","journal-title":"Bioinformatics"},{"key":"67865_CR80","doi-asserted-by":"publisher","first-page":"D916","DOI":"10.1093\/nar\/gkaa1087","volume":"49","author":"A Frankish","year":"2021","unstructured":"Frankish, A. et al. Gencode 2021. Nucleic Acids Res. 49, D916\u2013D923 (2021).","journal-title":"Nucleic Acids Res."},{"key":"67865_CR81","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","volume":"26","author":"MD Robinson","year":"2010","unstructured":"Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139\u2013140 (2010).","journal-title":"Bioinformatics"},{"key":"67865_CR82","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. Ser. B 57, 289\u2013300 (1995).","journal-title":"J. R. Stat. Soc. Ser. B"},{"key":"67865_CR83","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"67865_CR84","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1471-2105-14-7","volume":"14","author":"S Hanzelmann","year":"2013","unstructured":"Hanzelmann, S., Castelo, R. & Guinney, J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinforma. 14, 7 (2013).","journal-title":"BMC Bioinforma."},{"key":"67865_CR85","doi-asserted-by":"publisher","first-page":"D649","DOI":"10.1093\/nar\/gkx1132","volume":"46","author":"A Fabregat","year":"2018","unstructured":"Fabregat, A. et al. The reactome pathway knowledgebase. Nucleic Acids Res. 46, D649\u2013D655 (2018).","journal-title":"Nucleic Acids Res."},{"key":"67865_CR86","doi-asserted-by":"publisher","first-page":"11476","DOI":"10.1093\/nar\/gkz879","volume":"47","author":"G Casella","year":"2019","unstructured":"Casella, G. et al. Transcriptome signature of cellular senescence. Nucleic Acids Res. 47, 11476 (2019).","journal-title":"Nucleic Acids Res."},{"key":"67865_CR87","doi-asserted-by":"publisher","first-page":"5975","DOI":"10.1038\/onc.2008.213","volume":"27","author":"AL Fridman","year":"2008","unstructured":"Fridman, A. L. & Tainsky, M. A. Critical pathways in cellular senescence and immortalization revealed by gene expression profiling. Oncogene 27, 5975\u20135987 (2008).","journal-title":"Oncogene"},{"key":"67865_CR88","doi-asserted-by":"publisher","first-page":"2652","DOI":"10.1016\/j.cub.2017.07.033","volume":"27","author":"A Hernandez-Segura","year":"2017","unstructured":"Hernandez-Segura, A. et al. Unmasking transcriptional heterogeneity in senescent cells. Curr. Biol. 27, 2652\u20132660.e2654 (2017).","journal-title":"Curr. Biol."},{"key":"67865_CR89","doi-asserted-by":"publisher","first-page":"3927","DOI":"10.4161\/15384101.2014.973327","volume":"13","author":"M Purcell","year":"2014","unstructured":"Purcell, M., Kruger, A. & Tainsky, M. A. Gene expression profiling of replicative and induced senescence. Cell Cycle 13, 3927\u20133937 (2014).","journal-title":"Cell Cycle"},{"key":"67865_CR90","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/cdd.2017.172","volume":"25","author":"K Engeland","year":"2018","unstructured":"Engeland, K. Cell cycle arrest through indirect transcriptional repression by p53: I have a DREAM. Cell Death Differ. 25, 114\u2013132 (2018).","journal-title":"Cell Death Differ."},{"key":"67865_CR91","doi-asserted-by":"publisher","first-page":"9087","DOI":"10.1093\/nar\/gkz635","volume":"47","author":"S Uxa","year":"2019","unstructured":"Uxa, S. et al. DREAM and RB cooperate to induce gene repression and cell-cycle arrest in response to p53 activation. Nucleic Acids Res 47, 9087\u20139103 (2019).","journal-title":"Nucleic Acids Res"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-67865-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-67865-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-67865-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T00:06:03Z","timestamp":1769213163000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-67865-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,22]]},"references-count":91,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["67865"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-67865-4","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,22]]},"assertion":[{"value":"26 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The following authors have relationships with the companies listed: F Meric-Bernstam: AbbVie, Aduro BioTech, Aileron Therapeutics, Alkermes, AstraZeneca, Bayer Healthcare Pharmaceutical, Black Diamond, Biovica, Calithera Biosciences, Chugai Pharmaceutical, Curis, CytomX Therapeutics, Daiichi Sankyo, Debiopharm International, Ecor1 Capital, eFFECTOR Therapeutics, Eisai, European Organization for Research and Treatment of Cancer (EORTC), European Society for Medical Oncology (ESMO), F. Hoffmann-La Roche, FogPharma, Genentech, GT Apeiron, Guardant Health, Harbinger Health, IBM Watson, Immunomedics, Infinity Pharmaceuticals, Inflection Biosciences, Jackson Laboratory, Karyopharm Therapeutics, Klus Pharma, Kolon Life Science, Lengo Therapeutics, Loxo Oncology, Menarini Group, Mersana Therapeutics, Novartis, OnCusp Therapeutics, OrigiMed, PACT Pharma, Parexel International, Pfizer, Protai Bio, Puma Biotechnology, Samsung Bioepis, Sanofi, Seattle Genetics, Silverback Therapeutics, Spectrum Pharmaceuticals, Taiho Pharmaceutical, Takeda Pharmaceutical, Tallac Therapeutics, Tyra Biosciences, Xencor, Zentalis, Zymeworks. KK Hunt: Armada Health, AstraZeneca, Cairn Surgical, Eli Lilly & Co, Lumicell. S Damodaran: EMD Serono, Guardant Health, Novartis, Pfizer, Sermonix, Taiho. K Faia: Blueprint Medicines. K Keyomarsi: Apeiron, Blueprint Medicines, REPARE, Schrodinger, Novartis. All other authors declare no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"619"}}